A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in the United States of America

  1. Raje, N.
  2. Roodman, G.D.
  3. Willenbacher, W.
  4. Shimizu, K.
  5. García-Sanz, R.
  6. Terpos, E.
  7. Kennedy, L.
  8. Sabatelli, L.
  9. Intorcia, M.
  10. Hechmati, G.
Revista:
Journal of Medical Economics

ISSN: 1941-837X,  1369-6998

Any de publicació: 2018

Volum: 21

Número: 5

Pàgines: 525-536

Tipus: Article

DOI: 10.1080/13696998.2018.1445634 GOOGLE SCHOLAR lock_openAccés obert editor